[The gastrointestinal microbiome - vision and mission]

Area of Science:

• Microbiology
• Gastroenterology
• Pharmacology

Background:

• The gastrointestinal microbiome plays a crucial role in physiological functions and is implicated in various diseases.
• Dysbiosis, an alteration in the microbiome, is frequently associated with disease pathogenesis, though causality is not always established.
• Patients with Inflammatory Bowel Disease (IBD) exhibit specific microbial, fungal, bacteriophage, and archaeal patterns linked to metabolomic disturbances.

Purpose of the Study:

• To review the current status and challenges of fecal microbiome transfer (FMT) as a therapeutic strategy.
• To discuss the regulatory landscape of FMT in Germany and its impact on patient access.
• To highlight the emergence of microbiota-based therapeutics and their future implications.

Main Methods:

• Review of current clinical studies on FMT for various diseases.
• Analysis of regulatory frameworks governing FMT in Germany (Medicines Act).
• Examination of recent FDA approvals for microbiota-based therapeutics.

Main Results:

• Fecal microbiome transfer (FMT) is currently only guideline-recommended for recurrent Clostridioides difficile infection (rCDI).
• In Germany, FMT is restricted to individual healing attempts or clinical studies due to regulatory requirements and the need for extensive donor screening.
• The US FDA has approved microbiota-based therapeutics for rCDI prevention, signaling a shift towards standardized microbiome treatments.

Conclusions:

• While FMT holds therapeutic potential for numerous conditions, its application is limited by regulatory constraints and the need for rigorous donor safety protocols.
• The development and approval of standardized microbiota-based medicines represent a significant advancement, potentially increasing accessibility and efficacy.
• Further research and regulatory harmonization are essential to broaden the therapeutic use of microbiome-modulating interventions.